TriSalus Q2 revenue up 60% to $7.4M; DELIVER program launch; up to $50M debt financing closed

TriSalus Life Sciences, Inc.

2024-Q2 EPS reported -$0.81 revenue$13,821,000

Q2 revenue $7.4M (+60% YoY); gross margin improved to 88% from 83%.
Net loss $4.3M ($0.21 per share) vs $14.0M loss a year ago; operating loss $8.2M vs $11.4M.
Closed up to $50M debt facility with OrbiMed; drew $25M at close; cash $16.5M at June 30.
Warrant exchange completed; 79% of public warrants tendered, simplifying capital structure.
Expects final Phase 1 data for nelitolimod in uveal melanoma and pancreatic cancer in Q4 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.